Measuring neuroinflammation in hemiparkinsonian rhesus treated with iPSC-derived dopaminergic neuronal grafts using [18F]FEPPA PET

Conclusions: Our results demonstrate that [18F]FEPPA PET can be used as an in vivo biomarker of neuroinflammation after autologous or allogeneic iPSC-mDA intracerebral grafts. Post mortem analysis of the brains, including evaluation of CD68 immunoreactivity as a marker of microglia recruitment, is currently underway to validate the PET data.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Zammit, M., Olsen, M., Slesarev, M., Fuchs, K., Vermilyea, S., Metzger, J., Bjornson, K., Tao, Y., Zhang, S.-C., Emborg, M., Christian, B. Tags: Basic Science II (Neurosciences) Source Type: research